Table 7. Consensus on mHSPC management of monitoring.
| Pre-determined key question (yes/no) | Questions and response options | Completed | ||
|---|---|---|---|---|
| First round (n=23) | Second round (n=23) | |||
| No | 24. What ongoing monitoring by imaging do you recommend for the majority of patients with mHSPC on intensive systemic therapy (assuming that they do not develop new symptoms) in the current reimbursement environment? | Consensus | ||
| 1. PSA-prompted and no imaging until confirmed PSA progression | 8.7% (2) | |||
| 2. Regular imaging, e.g., every 3 months, regardless of PSA | 82.6% (19) | |||
| 3. Regular imaging, e.g., every 6–12 months, regardless of PSA | 8.7% (2) | |||
| No | 25. What ongoing monitoring by imaging do you recommend for the majority of patients with mHSPC on systemic therapy (assuming that they do not develop new symptoms) if all the options are reimbursed? | No consensus | Consensus | |
| 1. PSA-prompted and no imaging until confirmed PSA progression | 17.4% (4) | 8.7% (2) | ||
| 2. Regular imaging, e.g., every 3 months, regardless of PSA | 26.1% (6) | 4.3% (1) | ||
| 3. Regular imaging, e.g., every 6–12 months regardless of PSA | 56.5% (13) | 87.0% (20) | ||
| No | 26. For the majority of patients, what is your preferred imaging modality of patients with mHSPC for treatment monitoring? | Consensus | ||
| 1. Conventional imaging | 87.0% (20) | |||
| 2. Whole-body MRI | 0.0% (0) | |||
| 3. PSMA PET | 13.0% (3) | |||
Values are presented as % (number).
mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen; MRI, magnetic resonance imaging; PSMA PET, prostate-specific membrane antigen positron emission tomography.